Literature DB >> 1719025

Evaluation of first- and second-generation RIBA kits for detection of antibody to hepatitis C virus.

R K Chaudhary1, C MacLean.   

Abstract

Samples reactive by first-generation recombinant immunoblot assay (RIBA) to detect antibody to hepatitis C virus (anti-HCV) (RIBA-1 [Chiron, Calif.]) remained reactive by a second-generation test (RIBA-2) for HCV antibodies. A total of 75% of specimens indeterminate by RIBA-1 became reactive, 12.5% were nonreactive, and 12.5% remained indeterminate by RIBA-2. Among RIBA-1-nonreactive specimens, 12.0% became positive and 5.1% became indeterminate by RIBA-2. The antigens c33c and c22-3 have increased the sensitivity of RIBA-2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719025      PMCID: PMC270322          DOI: 10.1128/jcm.29.10.2329-2330.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

1.  Infectivity of blood that is immunoblot intermediate reactive on hepatitis C virus antibody testing.

Authors:  A Bellobuono; F Mozzi; G Petrini; A Zanella; G Sirchia
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

2.  Recombinant immunoblot assay for hepatitis C virus antibody as predictor of infectivity.

Authors:  F Ebeling; R Naukkarinen; J Leikola
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

4.  Chronic liver disease developing after outbreak of HBsAG-negative hepatitis in haemodialysis unit.

Authors:  R M Galbraith; A L Eddleston; B Portmann; R Williams; P E Gower
Journal:  Lancet       Date:  1975-11-08       Impact factor: 79.321

5.  Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

Authors:  M L Fletcher; J M Trowell; J Craske; K Pavier; C R Rizza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

6.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

7.  Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis.

Authors:  J W Mosley; A G Redeker; S M Feinstone; R H Purcell
Journal:  N Engl J Med       Date:  1977-01-13       Impact factor: 91.245

8.  Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population.

Authors:  M J Alter; R J Gerety; L A Smallwood; R E Sampliner; E Tabor; F Deinhardt; G Frösner; G M Matanoski
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226

  8 in total
  4 in total

1.  Performance of third-generation confirmatory tests for detection of antibody to hepatitis C virus.

Authors:  R K Chaudhary; H Jacobsen
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

2.  Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen.

Authors:  D Lavanchy; C Mayerat; B Morel; P Schneider; C Zufferey; J J Gonvers; A Pécoud; P C Frei
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

3.  Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

4.  Immunodominant regions within the hepatitis C virus core and putative matrix proteins.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.